title: Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44.
abstract: We show here that the anti-T lymphocyte immunoglobulin (ATG) can induce Treg cells following 24-h incubation in human peripheral blood mononuclear cells (PBMCs). The ATG-induced Treg cells express known cell surface markers (e.g., CD25, FoxP3) and suppress the proliferation of autologous responder PBMCs, stimulated with allogeneic PBMCs, when added into the mixed lymphocyte culture (MLC) at zero time point or 48 h later. We expanded the characteristics of the ATG-induced human Treg cells by showing that they express a novel biomarker designated "activated CD44". ATG-induced Treg cells retain their suppressor function after freezing and thawing or irradiation. Suppression of MLC by ATG-induced Treg cells is consistently seen when the Treg cells and the responder cells were derived from the same donor, but not when they derived from different donors. Finally, patients undergoing stem cell transplantation and conditioned with ATG generate in vivo Treg cells that suppress MLC.
authors: Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, Jerusalem, 91220, Israel.
authors: Orly
authors: O
authors: Shimony
authors: Arnon
authors: A
authors: Nagler
authors: Yechiel N
authors: YN
authors: Gellman
authors: Efrat
authors: E
authors: Refaeli
authors: Nir
authors: N
authors: Rosenblum
authors: Lora
authors: L
authors: Eshkar-Sebban
authors: Ronit
authors: R
authors: Yerushalmi
authors: Avichai
authors: A
authors: Shimoni
authors: Simon D
authors: SD
authors: Lytton
authors: Anfisa
authors: A
authors: Stanevsky
authors: Reuven
authors: R
authors: Or
authors: David
authors: D
authors: Naor
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000961:Antilymphocyte Serum / Q000276:immunology*; D002066:Busulfan / Q000494:pharmacology; D017252:CD3 Complex / Q000378:metabolism; D002648:Child; D015536:Down-Regulation / Q000276:immunology; D005260:Female; D051858:Forkhead Transcription Factors / Q000378:metabolism; D006402:Hematologic Diseases / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D007165:Immunosuppression Therapy; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D053699:Interleukin-7 Receptor alpha Subunit / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000528:radiation effects; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000494:pharmacology; D011485:Protein Binding; D011817:Rabbits; D011836:Radiation Tolerance / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000528:radiation effects; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000031:analogs & derivatives / Q000494:pharmacology; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D017252:CD3 Complex; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D018960:Hyaluronan Receptors; D053645:Interleukin-2 Receptor alpha Subunit; D053699:Interleukin-7 Receptor alpha Subunit; D019653:Myeloablative Agonists; C512542:thymoglobulin; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine